Pretax income is the income that a company earns before paying income taxes. Veracyte's pretax income for the
three
months ended in Dec. 2023 was $-30.5 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-76.6 Mil.
Veracyte's pretax margin was -31.03%.
During the past 13 years, Veracyte's highest Pretax Margin was -10.47%. The lowest was -76.91%. And the median was -33.46%.
Veracyte Pre-Tax Income Historical Data
The historical data trend for Veracyte's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Veracyte's Pre-Tax Income
For the Diagnostics & Research subindustry, Veracyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Veracyte's Pre-Tax Income falls into.
Veracyte Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Veracyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (NAS:VCYT) Pre-Tax Income Explanation
Veracyte's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Veracyte's highest Pretax Margin was -10.47%. The lowest was -76.91%. And the median was -33.46%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Veracyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCYT has been successfully added to your 